CN106138079A - A kind of liniment treating animal body surface parasitic disease and preparation method thereof - Google Patents
A kind of liniment treating animal body surface parasitic disease and preparation method thereof Download PDFInfo
- Publication number
- CN106138079A CN106138079A CN201610610639.0A CN201610610639A CN106138079A CN 106138079 A CN106138079 A CN 106138079A CN 201610610639 A CN201610610639 A CN 201610610639A CN 106138079 A CN106138079 A CN 106138079A
- Authority
- CN
- China
- Prior art keywords
- liniment
- body surface
- animal body
- parasitic disease
- dehydrated alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940040145 liniment Drugs 0.000 title claims abstract description 47
- 239000000865 liniment Substances 0.000 title claims abstract description 47
- 241001465754 Metazoa Species 0.000 title claims abstract description 39
- 208000030852 Parasitic disease Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960000935 dehydrated alcohol Drugs 0.000 claims abstract description 19
- 239000002480 mineral oil Substances 0.000 claims abstract description 19
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 19
- 239000008367 deionised water Substances 0.000 claims abstract description 18
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 18
- AGIQIKMGJVLKMA-NLRWUALESA-N (3ar,4as,5s,5ar,6ar)-5a-methyl-3-methylidene-5-(3-oxobutyl)-3a,4,4a,5,6,6a-hexahydrocyclopropa[f][1]benzofuran-2-one Chemical compound C1[C@@H]2C(=C)C(=O)O[C@@H]2C[C@]2(C)[C@@H](CCC(=O)C)[C@@H]21 AGIQIKMGJVLKMA-NLRWUALESA-N 0.000 claims abstract description 17
- AGIQIKMGJVLKMA-UHFFFAOYSA-N carabrone Natural products C1C2C(=C)C(=O)OC2CC2(C)C(CCC(=O)C)C21 AGIQIKMGJVLKMA-UHFFFAOYSA-N 0.000 claims abstract description 17
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims abstract description 15
- 229960002418 ivermectin Drugs 0.000 claims abstract description 15
- 229930192734 Avilamycin Natural products 0.000 claims abstract description 14
- 239000004190 Avilamycin Substances 0.000 claims abstract description 14
- XIRGHRXBGGPPKY-OTPQUNEMSA-N [(2r,3s,4r,6s)-6-[(2'r,3's,3ar,4r,4'r,6s,7ar)-6-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5s,6s)-6-[(2r,3as,3'ar,6'r,7r,7's,7ar,7'ar)-7'-acetyl-7'-hydroxy-6'-methyl-7-(2-methylpropanoyloxy)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,4'-6,7a-dihydro-3ah- Chemical compound O([C@H]1[C@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@H](O)CC2(O[C@]3(C)C[C@@H](O[C@H](C)[C@H]3O2)O[C@H]2[C@@H](OC)[C@@H](C)O[C@H]([C@@H]2O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC3[C@@H]([C@@H]4O[C@]5(O[C@H]4CO3)[C@@H]3OCO[C@H]3[C@@](O)([C@@H](C)O5)C(C)=O)OC(=O)C(C)C)O[C@@H]2COC)O[C@@H]1C)C(=O)C1=C(C)C(Cl)=C(O)C(Cl)=C1OC XIRGHRXBGGPPKY-OTPQUNEMSA-N 0.000 claims abstract description 14
- 229960005185 avilamycin Drugs 0.000 claims abstract description 14
- 235000019379 avilamycin Nutrition 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 8
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 7
- 239000004411 aluminium Substances 0.000 claims abstract description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000008117 stearic acid Substances 0.000 claims abstract description 7
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 10
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 7
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- -1 lactone ketone Chemical class 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 3
- 241000607479 Yersinia pestis Species 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- HVUMOYIDDBPOLL-UHFFFAOYSA-N 2-(3,4-Dihydroxyoxolan-2-yl)-2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)C1OCC(O)C1O HVUMOYIDDBPOLL-UHFFFAOYSA-N 0.000 abstract 1
- 229920001219 Polysorbate 40 Polymers 0.000 abstract 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 abstract 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 abstract 1
- 229940101027 polysorbate 40 Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 5
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000005660 Abamectin Substances 0.000 description 1
- 206010000351 Acariasis Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of liniment treating animal body surface parasitic disease, the weight of every 100ml liniment consists of: Carabrone 0.1～3.0g, ivermectin or avilamycin or doractin 0.1～1.0g, dehydrated alcohol 5.0～10.0g, polysorbate40 0～5.0g, deionized water 5.0～15.0g, sorbester p18 5.0～10.0g, ethyl acetate 3.0～10.0g, stearic acid aluminium powder 0.5～3.0g, surplus is mineral oil.The present invention further discloses its preparation method simultaneously.The liniment of the present invention is the most pest-resistant but also antibacterial, evident in efficacy；Its preparation technology is workable, utilizes and converts.
Description
Technical field
The invention belongs to veterinary medicine technical field, be specifically related to a kind of liniment treating animal body surface parasitic disease and
Preparation method.
Background technology
Animal body surface parasitic disease refers to the parasite colonizing in animal body surface and carries out multiplying, giving birth at animal body surface skin
Deposit, cause skin surface tissue injury, the pathological changes such as redness, rash block, incrustation occur, and shows the clinical table such as pruritus, pain
Existing a kind of disease.The animal body surface parasite of most animals group is acarid, louse and flea.Particularly with non-intensive management
Livestock and poultry animal, due to management not in place, anthelmintic is not in time, it is easier to cause the generation of primary disease.Additionally, breeding environment humidity mistake
Greatly, clear excrement frequency is low, animal feeding density is big etc. is this pathogenetic inducement.
In animal body surface parasitic disease, the most multiple with acariasis, various ages, the animal of kind all can infect.Propagate
Mode mainly by veterinary and healthy animal directly contact or by the colony house polluted by acarid and ovum thereof, pad careless and
Feeding and management apparatus mediate contact etc..Additionally, animal house is dark, moist, environment is unhygienic and malnutrition etc. all can promote this
Sick generation and development.Autumn and winter season, particularly rainy weather, this disease spreads the fastest.Although general ectozoa will not prestige
The side of body is to the life of animal, but due to animal skin pruritus, local hemorrhage is formed a scab, other pathogenic bacterium of easy secondary infection.If passed
Dye diffusion, then can cause overall poultry feed intake to decline, and production performance reduces, and feedstuff-meat ratio raises, and economic benefit reduces.
At present, the medicine of commercially available current therapies animal body surface parasite is all water formulation.This preparation also plays necessarily
Therapeutical effect, satisfactory for result.But owing to these dosage forms overwhelming majority is water constituent, or foreign minister is water.After being applied to skin, hold
Easily volatilizing, volatilize rear effective ingredient and crystallize out, effect is had a greatly reduced quality.Meanwhile, in order in order to be effective, it is necessary to frequently repeatedly to skin
Skin affected part is smeared.If people or house pet, this way can meet substantially, because quantity is few, easily operates.But for facing
The livestock and poultry animal of bed cultivation, quantity is the hugest, moreover domestic animal allows owner at will smear unlike obedient house pet, and they can be anti-
Anti-, thus cause medication to waste time and energy, to animal be also simultaneously a kind of strong stress, be unfavorable for that it grows.
Summary of the invention
It is an object of the invention to provide a kind of liniment treating animal body surface parasitic disease, its preparation method is provided simultaneously
It it is another goal of the invention of the present invention.
Based on above-mentioned purpose, the present invention adopts the following technical scheme that: a kind of liniment treating animal body surface parasitic disease, often
The weight of 100ml liniment consists of: Carabrone 0.1～3.0g, ivermectin or avilamycin or doractin 0.1～
1.0g, dehydrated alcohol 5.0～10.0g, Tween-40 0～5.0g, deionized water 5.0～15.0g, Arlacel-60 5.0～
10.0g, ethyl acetate 3.0～10.0g, stearic acid aluminium powder 0.5～3.0g, surplus is mineral oil.
Preferably, the weight of every 100ml liniment consists of: Carabrone 0.5～2.0g, ivermectin or Avermectin
Element or doractin 0.2～0.5g, dehydrated alcohol 7.0～8.0g, Tween-40 0～3.0, deionized water 5.0～10.0g, department
Dish-60 7.0～9.0g, ethyl acetate 5.0～8.0g, aluminium stearate 1.0～2.0g, surplus is mineral oil.
It is further preferred that the weight of every 100ml liniment consists of: Carabrone 1.0g, ivermectin 0.3g, nothing
Water-ethanol 8.0g, Tween-40 2.0g, deionized water 8.0g, Arlacel-60 8.0g, ethyl acetate 7.0g, aluminium stearate 1.5g,
Surplus is mineral oil.
Described mineral oil is white oil or liquid paraffin or mixture both it.
Described deionized water is sterilizing deionized water.
The preparation method of the liniment of described treatment animal body surface parasitic disease, comprises the following steps: (a) is by Radix Carpesii
Ester ketone, ivermectin or avilamycin or doractin, dehydrated alcohol, ethyl acetate, Arlacel-60 are mixed to get system A；(b)
Tween-40 is joined in deionized water, obtain system B；C stearic acid aluminium powder is joined in mineral oil and mixes by (), be heated to 120
～135 DEG C and maintain 20～40min, then it is cooled to less than-4 DEG C, obtain system C；D (), by system A, system B, the mixing of system C, adds
Enter in homogeneous emulsifying machine after emulsifying, constant volume, seal subpackage, to obtain final product.
In step (a), the concrete operations of system A are: first mixed with dehydrated alcohol by Carabrone；Again by Yi Wei bacterium
After element or avilamycin or doractin mix with ethyl acetate, join in the mixed liquor of Carabrone and dehydrated alcohol
Continue mixing；Add Arlacel-60 afterwards and mix system A that i.e. obtains.With direct mixed phase ratio, medicine dissolution when using aforesaid operations
Time is greatly shortened, and production efficiency significantly improves.
Usage and dosage: usage, local topical is smeared.Consumption, according to skin focus position size, need to smear focus
Entirely, it is ensured that focus all standing and smear uniformly.Reasonable recipe of the present invention, has specific aim to ectozoa treatment, uses peace
Entirely；Clinical practice determined curative effect, little to Animal stress, twice medication, it is spaced one week, i.e. can reach promising result.
In prescription of the present invention, the effect that each component plays wherein is:
1) dehydrated alcohol selected is as solvent, and in addition to dehydrated alcohol uses safety, dissolubility height, it is to medicinal liquid of the present invention also
There is certain antiseptic effect, and after smearing, may also function as convergence, Disinfection Effect at liniment of the present invention；
2) selecting acetic acid ethyl dissolution ivermectin or avilamycin or doractin, its effect reached is: ethyl acetate pair
The dissolubility of medicine is high, and pro-skin is effective, can bring medicine into ectozoa at liniment of the present invention after local skin is smeared
In parasitic " skin ulcer hole ", medicine is slowly discharged, and high concentration is filled, and plays permanent onset effect；
3) using mineral oil is final system foreign minister, and its effect reached is: mineral oil is petroleum fractionating extract, is difficult to fall
Solve, rotten, corrupt, inertia is strong, and to drug substance stable of the present invention；Mineral oil can be at affected area after liniment partial smearing of the present invention
Forming one layer of oil reservoir, this oil reservoir can prevent from affected area moisture content from distributing chapping, utilize rehabilitation；Simultaneously after medication, oil reservoir can be by
Focus surface covers without dead angle, by air exclusion, makes the substantial amounts of parasite in the inside be in anaerobic environment so that it is death by suffocation, greatly
Shortening greatly the course for the treatment of, and will not recur, this is also the innovative point of prescription of the present invention；
4), in the present invention, inventor confirms through great many of experiments, find Tween-40 and Arlacel-60 with the use of time than tween 80 and
Arlacel-80 with the use of time stable system, and when cryogenic conditions or the extraneous temperature difference are bigger, also do not have medicine layering shakiness
Determine phenomenon；
In addition to prescription advantage, the technique of the present invention is simple, it is not necessary to introduce complicated equipment, the GMP of general veterinary drug enterprises
Workshop can produce, and therefore production cost is low, beneficially the popularization on a large scale of medicine.
Therefore, compared with prior art, the present invention passes through prescription and the improvement of technique, and the technique effect reached is: first,
The liniment of the present invention is the most pest-resistant but also antibacterial, evident in efficacy, and is that water is different from foreign minister in prior art, including the water of this liniment
Portion, is difficult to volatilize, and medicine easily immerses skin, horny layer softening, promotes curative effect；Secondly, this product times for spraying reduces, and reduces dynamic
Thing stress, time saving and energy saving, reduce human cost, and stable in properties, withstand high/low temperature and transport test, cost performance is high, is beneficial to
Promote；Furthermore, the preparation technology of the present invention is workable, utilizes and converts.
Accompanying drawing explanation
Fig. 1 is the outward appearance material object photo of liniment of the present invention；
Fig. 2 is to confirm that the immiscible photo in kind of water met by liniment of the present invention；
Fig. 3 is the photo in kind confirming liniment density of the present invention less than water；
Fig. 4 be when tween 80 and Arlacel-80 with the use of time in 40 DEG C of constant temperature, the effect of accelerated test under 70% relative humidities
Fruit figure (placing 1 month)；
Fig. 5 be when tween 80 and Arlacel-80 with the use of time in 40 DEG C of constant temperature, the effect of accelerated test under 70% relative humidities
Fruit figure (placing 3 months).
Detailed description of the invention
Hereinafter will illustrate the present invention by embodiment, but these specific embodiments will limit this never in any form
Bright protection domain.
Embodiment 1-11
For making description succinct, provide putting on the skin of the treatment animal body surface parasitic disease described in embodiment 1-11 the most in the form of a table
The weight composition of agent, is specifically shown in Table 1.
The weight composition of every 100ml liniment in table 1 embodiment 1-11
。
The preparation method of the liniment of the treatment animal body surface parasitic disease described in embodiment 1-11, comprises the following steps:
A Carabrone is first mixed by () with dehydrated alcohol；Again by ivermectin or avilamycin or doractin and acetic acid
After ethyl ester mixing, join Carabrone and the mixed liquor of dehydrated alcohol continues mix；Add Arlacel-60 afterwards to mix
Close system A that i.e. obtains；
B Tween-40 is joined in deionized water by (), obtain system B；
C stearic acid aluminium powder is joined in mineral oil and mixes by (), be heated to 120～135 DEG C and maintain 20～40min, then lowering the temperature
To less than-4 DEG C, obtain system C；
D (), by system A, system B, the mixing of system C, adds in homogeneous emulsifying machine after emulsifying, constant volume seals subpackage, to obtain final product.
Embodiment 12
Difference from Example 1 is, the weight of every 100ml liniment consists of: Carabrone 0.1g, avilamycin or
Doractin 0.1g, dehydrated alcohol 10.0g, Tween-40 5.0g, deionized water 5.0g, Arlacel-60 5.0g, ethyl acetate
3.0g, stearic acid aluminium powder 0.5g, surplus is mineral oil.Remaining is all with embodiment 1.
Embodiment 13
Difference from Example 1 is, the weight of every 100ml liniment consists of: Carabrone 3.0g, avilamycin or
Doractin 1.0g, dehydrated alcohol 5.0g, Tween-40 3.0g, deionized water 15.0g, Arlacel-60 10.0g, ethyl acetate
10.0g, stearic acid aluminium powder 3.0g, surplus is mineral oil.Remaining is all with embodiment 1.
Embodiment 14
Difference from Example 1 is, the weight of every 100ml liniment consists of: Carabrone 0.5g, avilamycin or
Doractin 0.2g, dehydrated alcohol 8.0g, Tween-40 3.0, deionized water 10.0g, Arlacel-60 7.0g, ethyl acetate
5.0g, aluminium stearate 1.0g, surplus is mineral oil.Remaining is all with embodiment 1.
Embodiment 15
Difference from Example 1 is, the weight of every 100ml liniment consists of: Carabrone 2.0g, avilamycin or
Doractin 0.5g, dehydrated alcohol 7.0g, Tween-40 1.0, deionized water 5.0g, Arlacel-60 9.0g, ethyl acetate 8.0g,
Aluminium stearate 2.0g, surplus is mineral oil.Remaining is all with embodiment 1.
Test example 1-3
The product property of test example 1 product of the present invention and stability experiment
The product that the present invention obtains is the milky white liquid that quality is homogeneous, and its outward appearance material object photo is as shown in Figure 1；Fig. 2 card simultaneously
It is immiscible that water met by the liniment of the real present invention；Fig. 3 is then to confirm that liniment density of the present invention is less than water.
Embodiments of the invention 1-15 is sampled, each embodiment is carried out respectively room temperature placement, 40 DEG C of high temperature height
Wet placement, 4 DEG C of low temperature are placed and-20 DEG C of freezing placements, and separately sampled observation character when 0d, 15d, 30d, 90d and 180d,
Found that the product that each embodiment obtains all separates out situation without layering and medicine, there is preferable stability.
Meanwhile, in order to prove Tween-40 and Arlacel-60 with the use of effect, inventor use tween 80 and span-
80 with the use of contrasting, Fig. 4 and Fig. 5 give when tween 80 and Arlacel-80 with the use of time in 40 DEG C of constant temperature, 70% phase
To the design sketch of accelerated test under damp condition, Fig. 4 is to place after 1 month, it can be seen that the wild effect of layering occurs in medicine,
Fig. 5 is to place after 3 months, and medicine is in addition to there is layering, and upper strata color begins to change into light brown, and has brown solid material to analyse
The wild effect gone out.
Test example 2 safety experiment
Safety below by way of clinical experiment checking drug use.
Choose the Kun Ming mice 30 of about 20g, after abdominal part loses hair or feathers with depilatory, divide 3 groups, often group 10.First
Group is matched group, smears normal saline and processes, and second group is test 1 group, and skin scrapes " # " with pocket knife after having taken off hair, slightly to ooze
Blood is degree, repastes the liniment (embodiment 1 prepares) smearing the present invention；3rd group is test 2 groups, directly smears this after depilation
Bright liniment (embodiment 1 prepares), smears rear Continuous Observation one week, and record the drinking-water of each group of mice, diet, death,
The local skin feature of clinical manifestation and coating.
Experimental result:
1. each group mice drinking-water, diet are all normally, zero difference；
2. all there is not death in each group mice；
3. each group mice is without poisoning clinical manifestation；
4. all there are not the pathological signs such as redness, pain, local circulation obstacle in the coating position of three groups of mices；
Result shows: the liniment of the present invention all uses safety to healthy skin and damaged skin, will not cause dead and local is scorching
Property reaction.
Test example 3 test of pesticide effectiveness
Morbidity pig farm, somewhere, the growing and fattening pigs of 4 monthly ages, owing to breeding environment is poor, add ambient humidity greatly, clear excrement frequency is low, greatly
There is the focus of bronzing speckle, protrusion of surface in group's pig body surface, and focus pocket knife scrapes partial necrosis skin (sick strong boundary
Place) microscope inspection, it can be seen that there is the existence of acarid polypide, thus can be determined that erythema focus is to be caused by acarid.Sick animal
Body surface is become thin, and Mao Jiao's the part between the ribs and the hips hangs, and itching due to skin often rubs against wall, and chafing is serious, and skin depth is coarse, local depilation, sick
There is crust at stove more.By disease pig point blank not medication group, common Ivermectin Lotion group and liniment group of the present invention at random (by implementing
As a example by example 1 prepares) three groups, often group 20, same environment is separately raised, common Ivermectin Lotion and liniment of the present invention are coated with
Being put on the porcine skin affected area of test medication group, the first day once smears, and after 7 days, medication is smeared again, it is ensured that smear uniformly, test
Time limit is 10 days, is cultivated in the environment of dried sanitary by pig during test, in order to avoid environment superinfection.After medication, every day observes
Pig behavior and affected area recovery situation, and record, the results are shown in Table shown in 2.
Evaluation criterion:
Dead: during finger to finger test, test pig occurs dead ,-1 point；
Invalid: after referring to medication, though death does not occurs in test pig, but Symptoms and sign do not have and improve sign, 0 point；
Lapsing to: after referring to medication, test pig achieves certain effect, is in convalescence, 1 point；
Recovery from illness: after referring to medication, test pig returns to one's perfect health, and all behaviors premorbid and sign indifference, 2 points；
Total effective rate: lapse to after referring to medication and ratio × 100% that the test pig number fully recovered is total with this group test pig；
Protective rate: refer to that the total effective rate after medication deducts the total effective rate of the matched group of non-medication；
Table 2 uses liniment of the present invention and does not use the comparative efficacy test of liniment of the present invention
。
Result of the test: matched group need not any medicine, completely by the case of animal self-resistance, lapse to rate 10%, fully recover from an illness
More rate 0%, total effective rate is 10%；Common Ivermectin Lotion group, lapses to rate 40%, cure rate 35%, total effective rate 75%, this
Bright group, after the treatment ectozoa liniment using the present invention, lapses to rate 20%, cure rate 75%, and total effective rate is 95%, hence it is evident that
It is better than other two groups, the protective rate of infected animal is reached 85%.
Conclusion (of pressure testing): the liniment for treating animal body surface parasitic disease of the present invention treatment to animal body surface parasite
There is significant curative effect.
Claims (7)
1. the liniment treating animal body surface parasitic disease, it is characterised in that the weight of every 100ml liniment consists of: sky name
Essence lactone ketone 0.1～3.0g, ivermectin or avilamycin or doractin 0.1～1.0g, dehydrated alcohol 5.0～10.0g, tell
Temperature-40 0～5.0g, deionized water 5.0～15.0g, Arlacel-60 5.0～10.0g, ethyl acetate 3.0～10.0g, stearic acid
Aluminium powder 0.5～3.0g, surplus is mineral oil.
2. the liniment treating animal body surface parasitic disease as claimed in claim 1, it is characterised in that the weight of every 100ml liniment
Amount consists of: Carabrone 0.5～2.0g, ivermectin or avilamycin or doractin 0.2～0.5g, dehydrated alcohol
7.0～8.0g, Tween-40 0～3.0, deionized water 5.0～10.0g, Arlacel-60 7.0～9.0g, ethyl acetate 5.0～
8.0g, aluminium stearate 1.0～2.0g, surplus is mineral oil.
3. the liniment treating animal body surface parasitic disease as claimed in claim 2, it is characterised in that the weight of every 100ml liniment
Amount consists of: Carabrone 1.0g, ivermectin 0.3g, dehydrated alcohol 8.0g, Tween-40 2.0g, deionized water
8.0g, Arlacel-60 8.0g, ethyl acetate 7.0g, aluminium stearate 1.5g, surplus is mineral oil.
4. the liniment of the treatment animal body surface parasitic disease as described in claim 1 or 2 or 3, it is characterised in that described mineral oil
For both white oil or liquid paraffin or its mixture.
5. the liniment treating animal body surface parasitic disease as claimed in claim 4, it is characterised in that described deionized water is for going out
Bacterium deionized water.
6. the preparation method of the liniment of the treatment animal body surface parasitic disease described in claim 1 or 2 or 3 or 5, its feature exists
In, comprise the following steps: (a) is by Carabrone, ivermectin or avilamycin or doractin, dehydrated alcohol, acetic acid
Ethyl ester, Arlacel-60 are mixed to get system A；B Tween-40 is joined in deionized water by (), obtain system B；C () is by aluminium stearate
Powder joins in mineral oil and mixes, and is heated to 120～135 DEG C and maintains 20～40min, then being cooled to less than-4 DEG C, obtaining system
C；D (), by system A, system B, the mixing of system C, adds in homogeneous emulsifying machine after emulsifying, constant volume seals subpackage, to obtain final product.
7. the preparation method of the liniment for the treatment of animal body surface parasitic disease as claimed in claim 6, it is characterised in that step
A in (), the concrete operations of system A are: first mixed with dehydrated alcohol by Carabrone；Again by ivermectin or avilamycin
Or after doractin mixes with ethyl acetate, join Carabrone and the mixed liquor of dehydrated alcohol continues mix；It
After add Arlacel-60 and mix system A that i.e. obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610610639.0A CN106138079B (en) | 2016-07-29 | 2016-07-29 | A kind of liniment and preparation method thereof for treating animal body surface parasitic disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610610639.0A CN106138079B (en) | 2016-07-29 | 2016-07-29 | A kind of liniment and preparation method thereof for treating animal body surface parasitic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106138079A true CN106138079A (en) | 2016-11-23 |
| CN106138079B CN106138079B (en) | 2018-08-24 |
Family
ID=57327658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610610639.0A Expired - Fee Related CN106138079B (en) | 2016-07-29 | 2016-07-29 | A kind of liniment and preparation method thereof for treating animal body surface parasitic disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138079B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952372A (en) * | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
| CN101623256A (en) * | 2008-07-08 | 2010-01-13 | 中国农业科学院兰州畜牧与兽药研究所 | Ivermectin nanoemulsion drug combination and preparation method thereof |
| CN103788037A (en) * | 2012-11-02 | 2014-05-14 | 西北农林科技大学 | Method for purifying carabrone |
| CN105616500A (en) * | 2016-01-20 | 2016-06-01 | 吕欢 | Pharmaceutical composition for treating cestodiasis and preparation method thereof |
-
2016
- 2016-07-29 CN CN201610610639.0A patent/CN106138079B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952372A (en) * | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
| CN101623256A (en) * | 2008-07-08 | 2010-01-13 | 中国农业科学院兰州畜牧与兽药研究所 | Ivermectin nanoemulsion drug combination and preparation method thereof |
| CN103788037A (en) * | 2012-11-02 | 2014-05-14 | 西北农林科技大学 | Method for purifying carabrone |
| CN105616500A (en) * | 2016-01-20 | 2016-06-01 | 吕欢 | Pharmaceutical composition for treating cestodiasis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李祥: "《食品添加剂使用技术》", 31 January 2011 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106138079B (en) | 2018-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bonet et al. | Ethnobotany of Montseny biosphere reserve (Catalonia, Iberian Peninsula): plants used in veterinary medicine | |
| AU708703B2 (en) | Pharmaceutical compositions, based on etheric oils obtained from plants for use in the human and veterinary medical field | |
| Alawa et al. | Ethnoveterinary medical practice for ruminants in the subhumid zone of northern Nigeria | |
| Chagas et al. | Anthelmintic efficacy of neem (Azadirachta indica A. Juss) and the homeopathic product Fator Vermes® in Morada Nova sheep | |
| Riet-Correa et al. | Spontaneous acute poisoning by Crotalaria retusa in sheep and biological control of this plant with sheep | |
| Börkü et al. | Ivermectin is an effective treatment for bovine cutaneous papillomatosis | |
| Mushattat et al. | Effect of cold water extract Zingiber officinale on the Histological changes of the Experimental infection of domestic chickens with Ascaridia galii | |
| CN105168063A (en) | Skin care composition with acne removing effect and preparation method thereof | |
| CN118178530B (en) | Preparation method and application of ointment for treating cow hoof rot | |
| CN106511267A (en) | Compound moxidectin drops as well as preparation method and application thereof | |
| Oduola et al. | Histopathological changes in Wistar albino rats exposed to aqueous extract of unripe Carica papaya | |
| Mohamed et al. | Effect of repeated administration of Peganum harmala alcoholic extract on the liver and kidney in Albino mice: a histo-pathological study | |
| CN107582943B (en) | Compound traditional Chinese medicine transdermal spray for preventing and treating animal sarcoptidosis and preparation method thereof | |
| Offiah et al. | Survey of herbal remedies used by Fulani herdsmen in the management of animal diarrhoea in Plateau State, Nigeria | |
| CN106692397A (en) | Compound eprinomectin preparation as well as preparation method and application of compound eprinomectin preparation | |
| CN112043817A (en) | Anti-mite composition and application thereof | |
| CN106138079A (en) | A kind of liniment treating animal body surface parasitic disease and preparation method thereof | |
| Marsella et al. | Use of pentoxifylline in the treatment of allergic contact reactions to plants of the Commelinceae family in dogs | |
| Islam et al. | Clinicopathological studies on gentamicin toxicity in White Leghorn commercial layers | |
| CN115192642A (en) | Preparation method and application of composite biological preparation with parasite killing function and containing brevibacillus laterosporus and fermented traditional Chinese medicine | |
| CN105832764A (en) | Ointment for treating eczema mammae and preparation method of ointment | |
| Kotb et al. | Epidemiological studies of equine mange with special reference to different therapeutic protocols for effective treatment of Chorioptic mange | |
| CN105343245A (en) | Chinese medical spray for treating furunculosis, sore and furuncle and hemorrhoid | |
| Shahatha et al. | Effect of Marlubium vulgare Plant on Experimentally Infected Albino Mice with Trichomonas muris Parasite and Compare with Metronidazole Drug | |
| US2863804A (en) | Method of treating mange with extract of cedar leaf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180824 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |